FDA Staff Policy Guide Would Clarify Procedures Under SEC Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
The formal collaboration between the agencies "should produce just the right amount of consciousness among our employees about securities issues," FDA attorney Klasmeier says.
You may also be interested in...
FDA Develops Formal Procedure To Refer Misleading Communications To SEC
Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison between the agencies. FDA will provide "blanket" authorization to certain staff to share non-public information with SEC.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).